These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1560385)
41. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Mandema JW; Tuk B; van Steveninck AL; Breimer DD; Cohen AF; Danhof M Clin Pharmacol Ther; 1992 Jun; 51(6):715-28. PubMed ID: 1611810 [TBL] [Abstract][Full Text] [Related]
42. Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. van Steeg TJ; Freijer J; Danhof M; de Lange EC J Pharmacol Exp Ther; 2008 Mar; 324(3):1234-42. PubMed ID: 18162599 [TBL] [Abstract][Full Text] [Related]
43. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. Hardmeier M; Zimmermann R; Rüegg S; Pflüger M; Deuster S; Suter K; Donzelli M; Drewe J; Krähenbühl S; Fuhr P; Haschke M Clin Pharmacol Ther; 2012 May; 91(5):856-62. PubMed ID: 22453191 [TBL] [Abstract][Full Text] [Related]
44. Blockade of behavioral effects of bretazenil by flumazenil and ZK 93,426 in pigeons. Witkin JM; Acri JB; Gleeson S; Barrett JE Pharmacol Biochem Behav; 1997 Jan; 56(1):1-7. PubMed ID: 8981602 [TBL] [Abstract][Full Text] [Related]
45. Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy. Liefaard LC; Gunput RA; Danhof M; Voskuyl RA Epilepsia; 2007 Jul; 48(7):1378-87. PubMed ID: 17442008 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. Yuan R; Flockhart DA; Balian JD J Clin Pharmacol; 1999 Nov; 39(11):1109-25. PubMed ID: 10579141 [TBL] [Abstract][Full Text] [Related]
47. A pilot pharmacokinetic-pharmacodynamic study of benzodiazepine antagonism by flumazenil and aminophylline. Bonfiglio MF; Fisher-Katz LE; Saltis LM; Traeger SM; Martin BR; Nackes NA; Perkins TA Pharmacotherapy; 1996; 16(6):1166-72. PubMed ID: 8947991 [TBL] [Abstract][Full Text] [Related]
48. Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo. Visser SA; Gladdines WW; van der Graaf PH; Peletier LA; Danhof M J Pharmacol Exp Ther; 2002 Nov; 303(2):616-26. PubMed ID: 12388643 [TBL] [Abstract][Full Text] [Related]
49. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Dingemanse J; van Gerven JM; Schoemaker RC; Roncari G; Oberyé JJ; van Oostenbruggen MF; Massarella J; Segala P; Zell M; Cohen AF Br J Clin Pharmacol; 1997 Nov; 44(5):477-86. PubMed ID: 9384465 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. Hovinga S; Stijnen AM; Langemeijer MW; Mandema JW; van Bezooijen CF; Danhof M Br J Pharmacol; 1992 Sep; 107(1):171-7. PubMed ID: 1422570 [TBL] [Abstract][Full Text] [Related]
51. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. Tuk B; van Oostenbruggen MF; Herben VM; Mandema JW; Danhof M J Pharmacol Exp Ther; 1999 May; 289(2):1067-74. PubMed ID: 10215689 [TBL] [Abstract][Full Text] [Related]
52. Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals. Laurijssens BE; Greenblatt DJ J Pharm Pharmacol; 2002 Jan; 54(1):77-86. PubMed ID: 11829133 [TBL] [Abstract][Full Text] [Related]
53. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. Aarons L; Mandema JW; Danhof M J Pharmacokinet Biopharm; 1991 Oct; 19(5):485-96. PubMed ID: 1783988 [TBL] [Abstract][Full Text] [Related]
54. [RO 48-6791--a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam]. Hering W; Ihmsen H; Albrecht S; Schwilden H; Schüttler J Anaesthesist; 1996 Dec; 45(12):1211-4. PubMed ID: 9065257 [TBL] [Abstract][Full Text] [Related]
55. Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Bührer M; Maitre PO; Crevoisier C; Stanski DR Clin Pharmacol Ther; 1990 Nov; 48(5):555-67. PubMed ID: 2225714 [TBL] [Abstract][Full Text] [Related]
56. Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. Klotz U; Ziegler G; Ludwig L; Reimann IW J Clin Pharmacol; 1985 Sep; 25(6):400-6. PubMed ID: 2865275 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Greenblatt DJ; Ehrenberg BL; Gunderman J; Locniskar A; Scavone JM; Harmatz JS; Shader RI Clin Pharmacol Ther; 1989 Apr; 45(4):356-65. PubMed ID: 2702793 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Koopmans R; Dingemanse J; Danhof M; Horsten GP; van Boxtel CJ Clin Pharmacol Ther; 1988 Jul; 44(1):14-22. PubMed ID: 3391000 [TBL] [Abstract][Full Text] [Related]
59. Electroencephalographic effects of benzodiazepines. I. Choosing an electroencephalographic parameter to measure the effect of midazolam on the central nervous system. Bührer M; Maitre PO; Hung O; Stanski DR Clin Pharmacol Ther; 1990 Nov; 48(5):544-54. PubMed ID: 2225713 [TBL] [Abstract][Full Text] [Related]
60. A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Van Steveninck AL; Mandema JW; Tuk B; Van Dijk JG; Schoemaker HC; Danhof M; Cohen AF Br J Clin Pharmacol; 1993 Aug; 36(2):109-15. PubMed ID: 8398578 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]